glp-1 microdose tirzepatide Tirzepatide Microdose

WEGOVY (semaglutide) injection, for subcutaneous use

Inject the next dose on your usual day and time, then carry on treatment as normal, making sure theres at least 3 days between any 2 doses

This design enables three distinct pharmacological actions in a single molecule: GLP-1 receptor agonism : The two conjugated GLP-1 analog peptides activate GLP-1R to produce appetite suppression, glucose-dependent insulin secretion, glucagon suppression, and delayed gastric emptying GIP receptor antagonism : The antibody component blocks GIP signaling, which may reduce fat storage and modify energy metabolism Extended half-life : The antibody backbone provides a half-life of approximately 21 days -- three times longer than any approved weekly incretin therapy -- enabling once-monthly dosing The GIP antagonism approach is the most distinctive feature

Semaglutide 2.4 mg (Wegovy), a once-weekly GLP-1 receptor agonist licensed by the MHRA and recommended by NICE (Technology Appraisal TA875) for use in specific circumstances, demonstrated mean weight loss of approximately 14

Adequate sleep is crucial for mental health, so any significant sleep disturbances should be addressed

Those who suffer from discomfort due to muscle sprains, tears and damage may benefit from treatment with this peptide